IDE196 + Binimetinib + Crizotinib
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Trial Timeline
Jun 28, 2019 → Jun 15, 2027
NCT ID
NCT03947385About IDE196 + Binimetinib + Crizotinib
IDE196 + Binimetinib + Crizotinib is a phase 1/2 stage product being developed by IDEAYA Biosciences for Metastatic Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03947385. Target conditions include Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03947385 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Metastatic Uveal Melanoma